% | $
Quotes you view appear here for quick access.

Assured Guaranty Ltd. Message Board

bonds2stocks 5 posts  |  Last Activity: 21 hours ago Member since: Jul 14, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    nice move

    by fatnfifty May 27, 2015 3:57 PM
    bonds2stocks bonds2stocks 21 hours ago Flag

    seems like one of their abstracts looks better than mkt expectations.. asco palooza

  • Reply to

    Investor and Analyst Day Webcast

    by bauersteven12 May 27, 2015 9:37 AM
    bonds2stocks bonds2stocks 21 hours ago Flag

    drinks, patting on the back... who knows .. but.. i know last 30 mins of trading .. i "think" bottom may be in.. glad i sold some higher and I bought before the scramble in... still LONG and in some significant pain last 4 pts.. BUT .. if they have the secret novel sauce and there is a short term deal disclosed .... which i am confident- then technically the charts say we go to low 7's before June 8th.. I .. will be there - and - think i will be the tallest one on the floor- been a fun ride - more to come i am sure -

  • interesting-US Fed News Service, Including US State News
    Apr 7, 2015

    US Patent Issued to Compugen on April 7 for "Compositions and methods for treatment of drug resistant multiple myeloma" (American, Israeli Inventors)

    ALEXANDRIA, Va., April 7 -- United States Patent no. 8,999,335, issued on April 7, was assigned to Compugen Ltd. (Tel Aviv, Israel).

    "Compositions and methods for treatment of drug resistant multiple myeloma" was invented by Gad S. Cojocaru (Ramat HaSharon, Israel), Haiming Chen (West Hillls, Calif.) and James Berenson (Beverly Hills, Calif.).

    According to the abstract* released by the U.

    S. Patent & Trademark Office: "This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof."

    The patent was filed on Sept. 16, 2011, under Application No. 13/821,176.

    *For further information, including images, charts and tables, please visit:

  • bonds2stocks bonds2stocks Apr 3, 2015 3:07 PM Flag

    where do you see these results?

  • glad to see 2014 behind CVV - 6.7 mm dollars spent on Taiwan Glass..!! thats around $1.10 PER SHARE of earnings.. the way i see it.. if there is 10-20% growth this year , and we are at All time high bookings revenues etc.. will be 16 to 18 mm in gross profit before SGA - thats $2.50 to $3.0 bucks a share gross profit- THEN lets say 7 mm in SGA for 2015 ( recall 1.8 mm was for legal fees on 2014!! AND the 4.95 settlelment .. 6.7mm GONE) - SO - say CVV makes 9-10 mm in net income for 2015 thats 1.50 per share at say a 14 multiple ( S&P at 17 for 2019 numbers not 2015! ) you get to 21 bucks per share .. simple math NOT even looking beyond 2015 ... this will go HIGHER

28.90-0.13(-0.45%)May 28 4:00 PMEDT